Christian Moro/Shutterstock With one in four Australian adults experiencing problems with incontinence, some people look to ...

Theralase Technologies ( ($TSE:TLT) ) has shared an update. Theralase Technologies announced that its interim clinical data on the light-activated ...

Pacific Edge flags a legal challenge to a ruling that excludes its bladder cancer test from US public reimbursement ‘Pfizer ...

Discover a recent study, the RAIDER trial, in which 82% of patients received dose-escalated radiotherapy and experienced ...

Learn about urinary incontinence, its types, causes, and evidence-backed treatment strategies to regain control.

Discover a recent study that revealed that interstitial cystitis patients were older, predominantly female, and exhibited ...

U.S. Industrial Production Growth Slowed More Than Expected in May By Investing.com - Jun 17, 2022 1 By Geoffrey Smith Investing.com -- U.S. industrial output eked out its slowest growth in five ...

To evaluate possible predictors of elevated postvoid residual volume (PVR) following onabotulinumtoxinA administration in patients with idiopathic overactive bladder (OAB), a condition that may ...

ImmunityBio achieved a 55% disease-free rate at 12 months for BCG-unresponsive NMIBC and plans an sBLA submission in 2025. NSCLC Phase 2b trial (N=86) showed a median overall survival of 14.1 ...

Johnson & Johnson has initiated an application seeking Food and Drug Administration approval of its TAR-200 drug-device combination for the treatment of certain patients with bladder cancer.

Get Instant Summarized Text (Gist) An electroactive "scaffolding" biomaterial has been developed to enhance bladder tissue regeneration and function, outperforming current methods. This cell-free ...